Harrow Inc
HROW
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.37B
Close$
$13.51
59.2% downside
Current Fair Value
59.2% downsideOvervalued by 59.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.37 Billion |
|---|---|
| Enterprise Value | $1.58 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.14 |
| Beta | 0.24 |
| Outstanding Shares | 37,350,401 |
Return
| Return on Equity | -244.91% |
|---|---|
| Return on Assets | -8.93% |
| Return on Invested Capital | -7.37% |
Valuation & Multiples
| P/E Ratio | -33.33 |
|---|---|
| PEG | 7.48 |
| Price to Sales | 4.73 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 5.75 |
| Enterprise Value to EBIT | -68.33 |
| Enterprise Value to Net Income | -43 |
| Total Debt to Enterprise | 0.19 |
| Debt to Equity | 19.79 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.18
Average shareholder expectationRevenue Estimate
$70.35 M
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$0.16
Average shareholder expectationRevenue Estimate
$99.07 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3717▼ 13.38% |
|---|---|
| Total Calls | 1,334,800▲ 23.51% |
| Total Puts | 496,100▼ 9.19% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 58.30%▲ 0.78% |
|---|---|
| Total Invested | $924.43M▲ 22.35% |
| Investors Holding | 234▲ 7.00% |
ESG Score
No data
About Harrow Health Inc
125 employeesHarrow Health, Inc. owns a portfolio of ophthalmic pharmaceutical businesses, including ImprimisRx, the nation's leading ophthalmology outsourcing facility and pharmaceutical compounding business. The company holds large equity positions...